Results 81 to 90 of about 112,379 (218)

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

open access: yesMolecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang   +3 more
wiley   +1 more source

Their Duty Twice Over: Canadians in the Great Escape [PDF]

open access: yes, 2012
The Great Escape of March 1944 was the culmination of over a year’s planning and preparation by Allied airmen detained in Stalag Luft 3, a large prison camp in eastern Germany. The brainchild of a South African pilot, the plan called for the construction
Vance, Jonathan F.
core   +1 more source

Dammarenediol II enhances etoposide‐induced apoptosis by targeting O‐GlcNAc transferase and Akt/GSK3β/mTOR signaling in liver cancer

open access: yesMolecular Oncology, EarlyView.
Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee   +8 more
wiley   +1 more source

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

open access: yesMolecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat   +8 more
wiley   +1 more source

A regional technology transfer program [PDF]

open access: yes
The final report is presented for the North Carolina Science and Technology Research Center's 14th consecutive contract period as a NASA Industrial Applications Center, serving the information needs of nine Southeastern states. Included in the report are

core   +1 more source

Spartan Daily, February 24, 1961 [PDF]

open access: yes, 1960
Volume 48, Issue 72https://scholarworks.sjsu.edu/spartandaily/4126/thumbnail ...
San Jose State University, School of Journalism and Mass Communications
core   +2 more sources

The PI3Kδ inhibitor roginolisib (IOA‐244) preserves T‐cell function and activity

open access: yesMolecular Oncology, EarlyView.
Identification of novel PI3K inhibitors with limited immune‐related adverse effects is highly sought after. We found that roginolisib and idelalisib inhibit chronic lymphocytic leukemia (CLL) cells and Treg suppressive functions to similar extents, but roginolisib affects cytotoxic T‐cell function and promotion of pro‐inflammatory T helper subsets to a
Elise Solli   +7 more
wiley   +1 more source

Meeting the Challenge of Cyberterrorism: Defining the Military Role in a Democracy [PDF]

open access: yes, 2002
Denna forskningskonsumtion strävar efter att utifrån två frågeställningar undersöka dels var det deliberativa samtalets möjligheter och begränsningar ligger, dels undersöka hur det deliberativa samtalet påverkar lärarrollen i klassrummet.
Dunlap, Charles J., Jr.
core   +1 more source

Basroparib inhibits YAP‐driven cancers by stabilizing angiomotin

open access: yesMolecular Oncology, EarlyView.
Basroparib, a selective tankyrase inhibitor, suppresses Wnt signaling and attenuates YAP‐driven oncogenic programs by stabilizing angiomotin. It promotes AMOT–YAP complex formation, enforces cytoplasmic YAP sequestration, inhibits YAP/TEAD transcription, and sensitizes YAP‐active cancers, including KRAS‐mutant colorectal cancer, to MEK inhibition.
Young‐Ju Kwon   +4 more
wiley   +1 more source

Factors affecting the adoption of intranets and extranets by SMEs: a UK study [PDF]

open access: yes
The adoption of intranets and extranets involve major organisational innovation. Intranets alter the flows and content of internal communications, while extranets alter communications between the firm and its clients and suppliers. The paper identifies a
Berranger,Pascale,de, Windrum,Paul
core   +1 more source

Home - About - Disclaimer - Privacy